Celldex Therapeutics Closes $345M Public Stock Offering
Celldex Therapeutics, a clinical-stage biotech company, has closed a $345 million public stock offering, including the full exercise of the underwriters' option to purchase additional shares. The company sold nearly 12 million shares at $29 each, resulting in gross proceeds of approximately $345 million. Celldex plans to use these funds to advance its pipeline of antibody-based treatments for severe inflammatory, allergic, and autoimmune diseases, demonstrating investor confidence in its immune-based therapies.
Celldex sells nearly 11.9M shares, raises $345M in stock deal
Celldex Therapeutics announced the closing of its underwritten public offering, selling 11,896,750 common shares, including the full exercise of the underwriters' option for additional shares. The sale, priced at $29.00 per share, generated approximately $345 million in gross proceeds for the company. This financing operation finalizes a capital raise process that began in early April 2026.
Celldex Therapeutics Completes $345 Million Public Offering of Common Stock
Celldex Therapeutics has successfully closed its underwritten public offering, raising approximately $345 million in gross proceeds from the sale of 11,896,750 shares of common stock at $29.00 per share. This includes the full exercise of the underwriters' option for additional shares, reflecting strong market demand. The offering provides significant funding for Celldex, a biotechnology company focused on developing therapeutics for severe inflammatory, allergic, autoimmune, and other diseases.
Celldex Therapeutics announces public offering of common stock
The article states that Celldex Therapeutics has announced a public offering of its common stock. No further details about the offering size, terms, or intended use of proceeds are provided in the current content.
JPMorgan Chase & Co. Sells 49,046 Shares of Celldex Therapeutics, Inc. $CLDX
JPMorgan Chase & Co. reduced its stake in Celldex Therapeutics (NASDAQ:CLDX) by 21% in the third quarter, selling 49,046 shares but still holding 184,775 shares valued at $4.78 million. Despite this, other institutions like Wellington Management Group, Vestal Point Capital, and Eventide Asset Management significantly increased their positions in the biopharmaceutical company. Celldex Therapeutics recently missed earnings and revenue estimates, yet analysts maintain a "Moderate Buy" rating with a consensus price target of $44.45.
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
Celldex Therapeutics, Inc. announced the pricing of an underwritten public offering of 10,345,000 shares of its common stock at $29.00 per share, aiming to raise approximately $300 million. The company plans to use the net proceeds to fund the commercial launch of barzolvolimab, continue clinical and preclinical development, expand its bispecific antibody platform, and for general corporate purposes. Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor are acting as joint bookrunning managers for the offering.
Celldex Therapeutics (NASDAQ: CLDX) raises ~$282M net in $29 follow-on offering
Celldex Therapeutics announced a follow-on offering of 10,345,000 shares of common stock at $29.00 per share, aiming to raise approximately $281.8 million in net proceeds. The company plans to use these funds for commercial readiness of barzolvolimab, ongoing clinical and preclinical development, expanding its bispecific antibody platform, and general corporate purposes. The offering will result in an immediate dilution of $18.83 per share for new investors, and there is potential for further dilution from outstanding stock options.
Celldex Therapeutics Prices $29 Share Sale, Expects $282 Million Net From Underwritten Offering
Celldex Therapeutics is selling 10,345,000 shares of common stock at $29.00 per share through an underwriting agreement, expecting to net approximately $282 million. The company aims to use these proceeds to fund its operations and development programs. The offering is anticipated to close around April 6, 2026, with underwriters having an option to purchase additional shares.
Celldex (NASDAQ: CLDX) raises $300M in new common stock sale
Celldex Therapeutics has announced an underwritten public offering of 10,345,000 shares of common stock at $29.00 per share, aiming to raise approximately $300 million in gross proceeds. The company plans to use these funds for the potential U.S. commercial launch of barzolvolimab for CSU, continued clinical and preclinical development of its pipeline, expansion of its bispecific antibody platform, and general corporate purposes. The offering is expected to close around April 6, 2026, and underwriters have a 30-day option to purchase additional shares.
Celldex Announces Proposed Public Offering of Common Stock
Celldex Therapeutics, Inc. announced a proposed underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of shares. The company plans to use the net proceeds, along with existing funds, for commercial readiness and launch of barzolvolimab, clinical development of product candidates, growing its bispecific antibody platform, developing additional clinical pipeline candidates, and for general corporate purposes. Leerink Partners and TD Cowen are serving as joint bookrunning managers for the offering.
Celldex launches public offering of common stock By Investing.com
Celldex Therapeutics Inc. (NASDAQ:CLDX) has initiated an underwritten public offering of common stock to fund commercial readiness activities for barzolvolimab, its chronic spontaneous urticaria treatment, and to support further clinical development. The company's shares have gained 88% over the past year, and it maintains a strong financial position with more cash than debt and a high current ratio. Leerink Partners and TD Cowen are managing the offering.
Celldex Announces Proposed Public Offering of Common Stock
Celldex Therapeutics, Inc. (Nasdaq: CLDX) has initiated an underwritten public offering of its common stock and plans to grant underwriters an option to purchase an additional 15% of shares. The company intends to use the net proceeds, along with existing funds, to finance commercial readiness and launch of barzolvolimab, continue product candidate development, expand its bispecific antibody platform, and for general corporate purposes. Leerink Partners and TD Cowen are serving as joint bookrunning managers for the offering.
Celldex Therapeutics (NASDAQ: CLDX) files prospectus supplement for common stock offering
Celldex Therapeutics has filed a preliminary prospectus supplement for an at-the-market common stock offering under its existing registration. The offering aims to raise capital to fund commercial readiness and potential launch of barzolvolimab, continue clinical development, grow its bispecific antibody platform, and for general corporate purposes. While the per-share price and total shares offered are not yet specified, the filing provides detailed information on the company's financials, including shares outstanding, options, and net tangible book value, and outlines potential dilution risks for new investors.
CLDX PE Ratio & Valuation, Is CLDX Overvalued
Celldex Therapeutics Inc (CLDX) is currently considered undervalued based on its forward PS ratio relative to its five-year average, with a fair price estimated between $40.09 and $111.45 compared to its current price of $31.64. Despite being undervalued by this measure, its P/S ratio is significantly higher than the industry average, which the analysis deems unsustainable given its negative revenue growth. The article also provides details on CLDX's P/B ratio, FCF yield, and forward P/E and P/S ratios as of April 2, 2026.
Celldex Presents Positive Data from Phase 2 Chronic
Celldex (NASDAQ:CLDX) presented positive data from its Phase 2 clinical trials for barzolvolimab in chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) at the AAD 2026 Annual Meeting. The data showed rapid, profound, and durable improvements in patient quality of life across all measured domains. Barzolvolimab, a first-in-class antibody targeting mast cells, significantly reduced the impact of these conditions on patients' daily lives, suggesting its potential as a transformative treatment option.
Celldex says its hives drug sharply improved daily life in Phase 2
Celldex (NASDAQ: CLDX) presented positive Phase 2 data at AAD 2026 for its drug barzolvolimab, showing rapid, profound, and durable improvements in the quality of life for patients suffering from chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD). The drug achieved up to 71% complete response in CSU patients by Week 52, with 41% maintaining response seven months off therapy, and significant improvements were observed across all six Dermatology Life Quality Index (DLQI) domains. These results reinforce barzolvolimab's potential as a best-in-class treatment for chronic urticarias, with ongoing Phase 3 trials and topline data for CSU expected in Q4 2026.
Celldex Therapeutics stock gains after analyst upgrade
Celldex Therapeutics (NASDAQ:CLDX) shares rose 4.6% after Wolfe Research upgraded the stock from Underperform to Outperform with a $44 price target. Analyst Andy Chen cited positive news in 2025 that didn't translate to stock gains, but anticipates a better catalyst setup in 2026, especially with upcoming prurigo data in summer 2026. The firm believes barzolvolimab is severely undervalued and expects positive Phase 3 results.
Celldex Therapeutics stock hits 52-week high at 32.8 USD By Investing.com
Celldex Therapeutics (CLDX) stock has reached a new 52-week high of $33, marking a 57% increase over the last year and boosting its market capitalization to $2.06 billion. This surge follows positive developments, including promising Phase 2 data for its chronic urticaria treatment, barzolvolimab, and the early completion of its Phase 3 enrollment for the same drug. Analysts have varying price targets, with some suggesting potential overvaluation, though recent upgrades from Wolfe Research, Stifel, and Cantor Fitzgerald indicate strong confidence in the company's future.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Celldex Therapeutics (NASDAQ:CLDX) has received a "Moderate Buy" consensus recommendation from eleven brokerages, with an average 12-month price target of $44.50. This comes despite the company reporting Q4 EPS of -$1.22, missing estimates, and generating only $0.12 million in revenue against an expectation of $1.53 million, leading to negative margins. Analyst opinions are mixed, with some firms raising targets while others maintain underweight ratings, indicating divergent views on the stock's future.
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year High Following Analyst Upgrade
Celldex Therapeutics (NASDAQ:CLDX) shares reached a new 52-week high after Wolfe Research upgraded the stock to "outperform" with a $44 price target. Despite disappointing Q4 earnings that missed analyst expectations, the stock traded up 8.8% to $33.89, showcasing strong short-term inflows and an average "Moderate Buy" rating from analysts. Hedge funds have also been adjusting their positions in the biopharmaceutical company.
Celldex Therapeutics stock hits 52-week high at 32.8 USD
Celldex Therapeutics' stock hit a new 52-week high of $33, reflecting a 57% increase over the past year and raising its market capitalization to $2.06 billion. This surge is attributed to positive investor confidence and promising clinical data for barzolvolimab, its chronic urticaria treatment, including early completion of Phase 3 enrollment. Despite some InvestingPro data suggesting the stock might be overvalued, analysts have issued positive ratings and price targets, indicating confidence in the company's pipeline.
Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Wolfe Research
Wolfe Research upgraded Celldex Therapeutics (NASDAQ:CLDX) from "peer perform" to "outperform," setting a $44 target price, signaling a 42% potential upside. This upgrade comes despite Celldex missing Q4 earnings and revenue estimates, reporting a ($1.22) EPS versus an expected ($1.00) and $0.12 million in revenue against $1.53 million. However, several institutional investors, including Wellington Management Group, have significantly increased their stakes in the company, showcasing strong investor interest.
Eventide Asset Management LLC Has $48.10 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX
Eventide Asset Management LLC significantly increased its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) in Q3, now holding 1,859,095 shares valued at $48.10 million. Despite this increased institutional interest, Celldex Therapeutics recently missed earnings expectations and analysts have a "Moderate Buy" consensus rating with a target price of $44.50, though some maintain "Sell" ratings. The company, which is a clinical-stage biopharmaceutical firm, is trading near $29.51 with a $1.96 billion market cap.
Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts
Celldex Therapeutics highlighted significant progress in its barzolvolimab Phase III program for chronic spontaneous urticaria (CSU), completing enrollment six months ahead of schedule with 1,939 patients. The company anticipates several key data readouts in 2026, including prurigo nodularis in summer, Phase III CSU in Q4, and Phase II atopic dermatitis by year-end. Celldex emphasized barzolvolimab's potential for disease modification, noting high complete response rates and extended durability even after drug cessation, positioning it for severe CSU/angioedema and second-line advanced treatment.
Point72 files 13G/A: Celldex (CLDX) stake of 1,758,357 shares (2.6%)
Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has filed a 13G/A indicating a 2.6% stake in Celldex Therapeutics (CLDX). This amendment reports beneficial ownership of 1,758,357 shares of common stock as of December 31, 2025, with all reporting persons holding shared voting and dispositive power. The filing notes that these entities act as investment manager and general partner, respectively.
Celldex Therapeutics (CLDX) Is Up 5.7% After New Phase 2 Barzolvolimab Data in Inducible Urticaria
Celldex Therapeutics saw its stock rise by 5.7% following the presentation of new positive Phase 2 data for its antibody barzolvolimab in chronic inducible urticaria. The data, presented at the 2026 AAAAI Annual Meeting, showed rapid and sustained improvements in disease control upon both initial and repeat treatment. This reinforces the potential of barzolvolimab's mast-cell–targeting mechanism, despite the company's current loss-making status and reliance on future clinical success and financing.
Chronic Spontaneous Urticaria Pipeline Expands with 25+ Therapies and 20+ Companies Advancing Next-Generation Treatments by 2026 | DelveInsight
The Chronic Spontaneous Urticaria (CSU) pipeline is growing, with over 25 investigational therapies from more than 20 companies under development. Key therapies include remibrutinib (Novartis), barzolvolimab (Celldex Therapeutics), JYB1904 (Jemincare), and YH35324 (Yuhan Corporation), all showing promise in clinical trials for treating chronic hives and related symptoms. DelveInsight's report provides a detailed overview of this dynamic landscape, including clinical-stage and preclinical products, and highlights significant advancements aimed at addressing unmet medical needs in CSU.
Celldex Therapeutics stock hits 52-week high at $31.36 By Investing.com
Celldex Therapeutics (CLDX) has reached a new 52-week high of $31.31, increasing its market capitalization to $2.07 billion. This milestone reflects a 42% stock price increase over the past year, indicating strong investor confidence. The company's recent advancements in clinical trials, including promising Phase 2 data for barzolvolimab and early completion of Phase 3 enrollment, have contributed to this growth, though InvestingPro notes the stock may be trading above its Fair Value.
Celldex Therapeutics stock hits 52-week high at $31.36
Celldex Therapeutics (CLDX) has reached a new 52-week high of $31.31, increasing its market capitalization to $2.07 billion, after a 42% stock price surge over the past year. This milestone is driven by advancements in its chronic urticaria treatment, barzolvolimab, including promising Phase 2 data and ahead-of-schedule enrollment for its Phase 3 program. Despite being potentially overvalued according to InvestingPro, analysts from Stifel and Cantor Fitzgerald maintain Buy and Overweight ratings, respectively, with price targets significantly above the current stock price.
A Look At Celldex Therapeutics (CLDX) Valuation After New Barzolvolimab Urticaria Data
Celldex Therapeutics (CLDX) recently presented new Phase 2 data for barzolvolimab in urticaria, contributing to the stock's 30-day return of 23.86%, despite the company reporting a US$258.76 million annual loss. The article examines the company's valuation, noting its Price/Book ratio of 3.7x is above the US Biotech industry average but below broader peer averages, signaling mixed investor sentiment. A Discounted Cash Flow model suggests the stock may be significantly undervalued, with a future cash flow estimate of $96.93 compared to its current share price of $29.43.
New Barzolvolimab Urticaria Data And Losses Might Change The Case For Investing In Celldex Therapeutics (CLDX)
Celldex Therapeutics reported new positive Phase 2 data for barzolvolimab in chronic urticaria at the AAAAI Annual Meeting, showing its potential for retreatment efficacy. Despite strong clinical signals, the company posted a net loss of US$258.76 million against US$1.55 million in revenue for 2025, highlighting significant financing risk. The article suggests that while the clinical data is promising, the financial challenges and stock valuation concerns remain critical for investors.
TD Asset Management Inc Decreases Stake in Celldex Therapeutics, Inc. $CLDX
TD Asset Management Inc. recently reduced its stake in Celldex Therapeutics, Inc. by 27.7% during the third quarter, selling 35,428 shares and retaining 92,450 shares valued at approximately $2.39 million. This move comes as analysts have a "Moderate Buy" consensus for CLDX, with price targets ranging from $24 to $68, despite the company missing quarterly earnings expectations and showing negative profitability. Other institutional investors have both increased and decreased their positions in Celldex Therapeutics.
Propel Bio Management LLC Makes New $4.01 Million Investment in Celldex Therapeutics, Inc. $CLDX
Propel Bio Management LLC has made a new $4.01 million investment in Celldex Therapeutics (CLDX), acquiring 155,000 shares, which now represents 4.0% of its portfolio. This comes as Celldex reported wider-than-expected quarterly losses and lower revenue than anticipated. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $44.50.
Fisher Asset Management LLC Acquires 104,949 Shares of Celldex Therapeutics, Inc. $CLDX
Fisher Asset Management LLC increased its stake in Celldex Therapeutics (NASDAQ:CLDX) by 12.8% during the third quarter, acquiring an additional 104,949 shares to own a total of 927,157 shares valued at approximately $23.99 million. This move comes as other institutional investors have also adjusted their positions in the biopharmaceutical company. Despite a recent earnings per share miss and weak revenue, Celldex Therapeutics holds a consensus "Moderate Buy" rating from analysts with an average price target of $44.50.
Segall Bryant & Hamill LLC Buys 140,709 Shares of Celldex Therapeutics, Inc. $CLDX
Segall Bryant & Hamill LLC increased its stake in Celldex Therapeutics (NASDAQ:CLDX) by 36.3% during the third quarter, acquiring an additional 140,709 shares. This move is part of a broader trend of institutional accumulation of CLDX stock, despite the company reporting an EPS miss and lower-than-expected revenue. Analysts maintain a "Moderate Buy" rating for Celldex, with an average price target of $44.50.
CLDX SEC Filings - Celldex Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page provides access to Celldex Therapeutics (CLDX) SEC filings, including 10-K, 10-Q, and 8-K reports, offering detailed information on the company's clinical programs, financial position, and material events. It highlights recent filings such as the Q3 2025 10-Q revealing $583.2M liquidity and a $177.4M YTD loss, an 8-K furnishing Q3 2025 results, and another 8-K on Phase 2 Barzolvolimab EoE results, alongside insider trading disclosures. The platform also offers AI-powered summaries to help investors understand key aspects of lengthy documents.
Assessing Celldex Therapeutics (CLDX) Valuation After Positive Barzolvolimab Phase 3 Enrollment And Phase 2 Data
Celldex Therapeutics (CLDX) has seen increased attention and a significant share price increase following early completion of Phase 3 enrollment for its barzolvolimab trials and positive long-term Phase 2 data. Despite recent gains, the stock's Price to Book ratio of 3.8x is considered good value compared to peers, and a Discounted Cash Flow model suggests a substantial undervaluation at $208.73 per share against its current price of $30.09. However, the company faces execution risks related to its clinical programs and ongoing net losses.
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD)
Celldex presented new positive data from its Phase 2 Open Label Extension study for barzolvolimab, showing that retreatment in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) achieved rapid improvement and similar profound efficacy as the initial treatment. This reinforces barzolvolimab's potential as a first-in-class and best-in-disease treatment by targeting mast cells. A global Phase 3 trial (EMBARQ-ColdU and SD) is currently enrolling patients.
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Celldex presented new positive data for its drug barzolvolimab, showing that retreatment for Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) achieved similar profound efficacy as the initial treatment. The data, presented at the 2026 AAAAI Annual Meeting, highlight that barzolvolimab, which targets mast cells, provides rapid improvement in urticaria control after symptom recurrence. These findings support barzolvolimab as a potential best-in-class treatment option and indicate that intermittent treatment schedules are viable, with a global Phase 3 trial currently enrolling patients.
Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory
This article presents a bullish thesis for Celldex Therapeutics, Inc. (CLDX), highlighting its lead compound barzolvolimab ("barzo") which is entering a second Phase III trial for chronic inducible urticaria (CIndU) and has potential for premium pricing and expansion into multiple indications. The company's second mast cell-targeting antibody, CDX-622, also shows promise, contributing to a strong investment case driven by clinical milestones and significant market opportunities. The analysis suggests CLDX offers substantial upside, although it notes that the stock is not among the top hedge fund holdings.
Celldex Presents Additional Positive Data from Phase 2
Celldex (NASDAQ:CLDX) presented additional positive data from its Phase 2 clinical trials of barzolvolimab for chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) at the 2026 AAAAI Annual Meeting. The data highlights barzolvolimab's novel mechanism targeting mast cells, showing sustained off-treatment efficacy in CSU patients, suggesting disease modification, and significant improvements in quality of life for ColdU and SD patients. Celldex has also completed enrollment for its global Phase 3 CSU program and initiated a Phase 3 study for ColdU and SD, positioning barzolvolimab as a potential first-in-class and best-in-disease treatment.
Celldex Presents Additional Positive Data from Phase 2
Celldex announced positive additional data from its Phase 2 clinical trials of barzolvolimab for chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD). The data, presented at AAAAI 2026, demonstrated sustained off-treatment efficacy, improved quality of life, and reduced disease impact for patients, suggesting barzolvolimab's potential as a disease-modifying treatment. The company also announced the completion of enrollment for its global Phase 3 program in CSU and ongoing enrollment for Phase 3 studies in ColdU and SD.
Celldex Presents Additional Positive Data from Phase 2
Celldex presented additional positive data from its Phase 2 clinical trials for barzolvolimab in chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD). The data highlighted sustained off-treatment efficacy in CSU patients, suggesting disease modification, and significant improvements in quality of life for ColdU and SD patients. Barzolvolimab, a novel mast cell targeting antibody, aims to provide rapid, profound, and durable efficacy for these debilitating conditions, with global Phase 3 enrollment completed for CSU and ongoing for ColdU/SD.
CLDX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of Celldex Therapeutics Inc (CLDX), including its income statement, balance sheet, and cash flow data derived from SEC filings. The company exhibits low profitability and significant revenue decline, but a strong balance sheet with low leverage and high liquidity. Celldex Therapeutics Inc has an estimated cash runway of approximately 2 months and a low Piotroski F-Score, indicating weak financial health.
Celldex Therapeutics Rallied 24% After Clinical Update: Here’s What Analysts See Next
Celldex Therapeutics (CLDX) stock surged over 24% after the company announced the completion of enrollment for its Phase 3 barzolvolimab trials for chronic spontaneous urticaria. Despite reporting minimal revenue and a wider net loss for Q4, investors focused on the positive pipeline momentum, which also came ahead of multiple scientific and investor conferences. Analysts now project a stock price target of $53 for CLDX.
Celldex Therapeutics (CLDX) Is Up 34.0% After Completing Global Phase 3 Enrollment for Barzolvolimab in CSU - Has The Bull Case Changed?
Celldex Therapeutics announced it has completed enrollment for its global Phase 3 EMBARQ trials of barzolvolimab in chronic spontaneous urticaria, involving 1,939 patients across 43 countries. The market has reacted positively to this news, with shares up 34% in the last week, reflecting reduced timing risk for pivotal readouts. However, the company remains largely dependent on barzolvolimab given its early-revenue, loss-making status, and investors are now focused on data quality, safety, and financing needs.
November 20th Options Now Available For Celldex Therapeutics (CLDX)
New options for Celldex Therapeutics (CLDX) began trading today, expiring on November 20th. These new contracts offer potential opportunities for options sellers due to the longer time until expiration, allowing for higher premiums. The article highlights specific put and call contracts, detailing potential returns and risks for investors interested in buying or selling CLDX options.
Celldex: Fourth Quarter Financial Overview
Celldex Therapeutics reported a net loss of $81.3 million, or $1.22 per share, for the fourth quarter, which was higher than analysts' expectations. The biopharmaceutical company also recorded revenue of $121,000 for the quarter, missing analyst projections. For the full year, Celldex's total loss amounted to $258.8 million, with annual revenue of $1.5 million.
Celldex Therapeutics Opens with a 6.56% Gain, Outpacing S&P 500's 0.69% Increase
Celldex Therapeutics, Inc. today saw a significant gain of 6.56%, outperforming the S&P 500's 0.69% increase. Despite this positive movement, the company has faced considerable financial challenges over the past five years, including declining net sales and a plummeting operating profit. Its current market capitalization stands at USD 1,530 million, reflecting a complex financial outlook.
Celldex Therapeutics stock hits 52-week high at 30.66 USD
Celldex Therapeutics (CLDX) stock reached a 52-week high of $30.66, reflecting a 47.46% increase over the past year, though InvestingPro analysis suggests it may be overvalued. The company holds more cash than debt, supporting financial flexibility. Recent developments include the completion of a large Phase 3 trial for barzolvolimab in chronic spontaneous urticaria ahead of schedule and the initiation of another global Phase 3 trial for cold urticaria and symptomatic dermographism.
